Climedo is a technology company.
Climedo has raised $6.0M across 1 funding round.
Climedo has raised $6.0M in total across 1 funding round.
Climedo has raised $6.0M in total across 1 funding round.
Climedo's investors include Target Partners.
Climedo Health GmbH is a Munich-based technology company founded in 2017 that provides a cloud-based, all-in-one platform for electronic data capture (EDC), electronic patient-reported outcomes (ePRO), electronic clinical outcome assessments (eCOA), eConsent, and telemedicine solutions tailored for hybrid and decentralized clinical trials, non-interventional studies, and real-world evidence (RWE) generation.[1][2][3][4] It serves pharmaceutical companies, biotech firms, medtech manufacturers, contract research organizations (CROs), hospitals, research institutes, academia, and public health offices by enabling efficient data collection from patients, physicians, and sites in real-world settings, solving challenges like slow recruitment, poor data quality, high costs, and low patient engagement through patient-centric, modular tools that boost completion rates to 90% and cut manual work by 80%.[1][2][3][4] With over 1.7 million patients enrolled, Climedo accelerates studies by 18-24 months, enhances real-time insights via dashboards, and supports post-market surveillance, driving faster medical innovation access for patients.[1][3][4]
Climedo was founded in Munich, Germany, in 2017 by co-founders Sascha (CEO) and Veronika (COO), though specific details on their prior backgrounds are not detailed in available sources.[1][3] The company emerged to address inefficiencies in traditional clinical research, particularly in post-market validation and decentralized data capture, by developing a secure, web-based platform that connects stakeholders like pharma partners, study sites, physicians, and patients.[2][4] Early traction came from its focus on hybrid trials and RWE, quickly gaining trust among pharma, medtech, CROs, and academia, with over 1.7 million patients enrolled to date; pivotal growth included adopting AWS for scalability in the Europe (Frankfurt) region and serving around 150 public health offices during high-demand periods like symptom tracking.[1][4]
Climedo rides the wave of decentralized clinical trials (DCT) and digital health transformation, capitalizing on post-pandemic shifts toward remote, hybrid study designs amid rising demand for real-world evidence and faster drug/device validation.[2][4][6] Timing aligns with regulatory pushes for patient-centric trials (e.g., FDA focus on survival endpoints, AI opportunities in research) and market forces like cost pressures on pharma/medtech, where traditional methods lag in efficiency and engagement.[3][6] By digitizing data flows and fostering stakeholder connectivity, Climedo influences the ecosystem through higher-quality data, innovative designs, and accelerated launches—reaching more patients faster—while enabling European data sovereignty via AWS.[1][4]
Climedo is poised for expansion with ongoing platform enhancements like 2023's progression/benchmarking upgrades and AWS scalability, targeting more global pharma/biotech trials amid DCT growth.[4][6] Trends like AI integration for endpoints, hybrid trial adoption (e.g., IQVIA/Veeva strategies), and RWE demands will propel it, potentially doubling patient enrollment as medtech surveillance needs rise.[6] Its influence may evolve from European leader to broader digital trial enabler, sustaining momentum through modular innovations that keep clinical research accessible, efficient, and patient-focused—ultimately delivering better healthcare faster.[1][2][3]
Climedo has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $6.0M Seed | Target Partners |